Hanchung Medical has launched “Etherics 200mg PDLLA,” a PDLLA (poly-D,L-lactic acid)-based collagen stimulator designed to promote the skin’s natural collagen production, making it highly effective for wrinkle improvement.

At the same time as the launch of Etherics 200mg PDLLA, the company signed an exclusive supply agreement in China with a local Chinese partner. Through this agreement, the partner will take full responsibility for sales, marketing, and distribution in the Chinese market. Hanchung Medical plans to further strengthen its presence in the Asian regenerative medicine and aesthetic medical market through this strategic partnership. According to company materials, the product is presented as a PDLLA powder formulation, with a recommended treatment interval of 4–6 weeks, an expected duration of 1.5 to 2 years (depending on individual variation), a storage temperature of 1–30°C, and a shelf life of 36 months.

Supply will be carried out through designated distribution channels for medical institutions. As a collagen stimulator, the product is administered into the dermal layer, where it activates fibroblasts and induces collagen regeneration. It may also selectively disrupt fat cell membranes to reduce fat volume, while helping to maintain and improve skin elasticity through collagen synthesis. In the aesthetic and regenerative medicine market, demand for improved skin quality and a preference for natural-looking volume and contouring continue to grow steadily. At the same time, demand for standardized treatment protocols and post-procedure management information is also increasing. Hanchung Medical plans to enhance product credibility by strengthening its content strategy, accumulating clinical and usability data, and advancing safety-focused guidance systems. In addition, the company aims to improve supply stability and accessibility by expanding global partnerships.